Neurodegenerative disease Archives

In Depth 21 Apr 2023

Gut microbiome: a promising target for Parkinson’s

Home to around a thousand microbial species, the gut’s role in nutrient and drug metabolism is pivotal for immune function. As trillions of bacteria that thrive in the gastrointestinal system aid in the metabolic activity, the gut microbiome can also be influential in therapeutic research for an array of diseases, including Parkinson’s. And of late, […]

April 21, 2023 - 8 minutesmins - By Roohi Mariam Peter

News and Trends 31 Mar 2023

€260M fund addresses dementia investment shortfall

EQT Life Sciences has closed its inaugural LSP Dementia Fund, raising approximately €260 million ($283 million) in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million ($108.9 million). The LSP Dementia Fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies […]

March 31, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 8 Mar 2023

The challenges of tackling dementia in women

Dr Andrea Pfeifer, chief executive officer of AC Immune SA, talks to Labiotech about dementia research, and how dementia affects women. She also addresses how vital research is when it comes to addressing women’s health. Dementia is a leading cause of death in women, but it doesn’t get the attention of other diseases, such as […]

March 8, 2023 - 5 minutesmins - By Jim Cornall

More News! 2 Mar 2023

Could new dementia treatment come from intestinal bacteria discovery?

Dementia with Lewy bodies (DLB), one of the most common forms of dementia, has no cure. Previous studies suggested that gut bacteria play a role in Parkinson’s disease, another neurodegenerative disorder, but the bacteria involved in dementia with Lewy bodies had not been identified. Now, a group led by researchers at the Nagoya University Graduate […]

March 2, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Minoryx Therapeutics announces X-linked adrenoleukodystrophy data

Minoryx Therapeutics has announced that data from its phase 2/3 ADVANCE clinical trial of lead candidate, leriglitazone, has been published in The Lancet Neurology. The trial, assessing the efficacy and safety of leriglitazone in male patients with adrenomyeloneuropathy, is the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients. X-linked adrenoleukodystrophy (X-ALD) […]

February 14, 2023 - 4 minutesmins - By Jim Cornall

MDI Biosciences Cardiff University. Photo/Cardiff University

News and Trends 14 Feb 2023

Astex and Cardiff University Medicines Discovery Institute to collaborate on neurodegenerative diseases

Astex Pharmaceuticals (UK), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system and The Medicines Discovery Institute, Cardiff University (MDI) have entered into a multi-year, multi-million-pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases. The collaboration […]

February 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

Ubiquigent and University of Glasgow to collaborate on drug discovery

Ubiquigent Limited, a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neruodegenerative, renal, and cardiovascular diseases. Overseen by structural biology experts […]

January 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases

The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has issued a call for multinational research on large scale analysis of OMICS data for drug-target finding in neurodegenerative diseases. Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 50 million people with Alzheimer’s […]

January 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Japanese research offers hope for Fukuyama muscular dystrophy patients

Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests itself in the form of a severe neuromuscular disorder. One form of FCMD is caused by a genetic abnormality in the fukutin (FKTN) gene. The genetic anomaly blocks the chemical glycosylation of a biologically important […]

December 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Scientists identify genetic variant causing ALS in some patients

Researchers at Nagoya University in Japan have identified a novel genetic variant found in some patients with amyotrophic lateral sclerosis (ALS). Employing human-induced pluripotent stem (iPS) cells, they detailed the process by which this variant relates to ALS. The investigators say they expect this mechanism to be a new therapeutic target for ALS treatment. The […]

December 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Immune cells in ALS patients can predict the course of the disease

By measuring immune cells in the cerebrospinal fluid when diagnosing ALS, it is possible to predict how fast the disease may progress. This according to a study from Karolinska Institutet in Sweden, which has been published in Nature Communications. ALS is a rare, but fatal, disease that affects the nerve cells and leads to paralysis […]

November 23, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurodegenerative disease

Gut microbiome: a promising target for Parkinson’s

€260M fund addresses dementia investment shortfall

The challenges of tackling dementia in women

Could new dementia treatment come from intestinal bacteria discovery?

Minoryx Therapeutics announces X-linked adrenoleukodystrophy data

Astex and Cardiff University Medicines Discovery Institute to collaborate on neurodegenerative diseases

Ubiquigent and University of Glasgow to collaborate on drug discovery

JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases

Japanese research offers hope for Fukuyama muscular dystrophy patients

Scientists identify genetic variant causing ALS in some patients

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Immune cells in ALS patients can predict the course of the disease

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!